China Drug Price Reform Takes Shape: Price Ceilings Out, Reimbursement Caps In
This article was originally published in The Pink Sheet Daily
Executive Summary
China’s NDRC plans to substitute reimbursement caps for maximum ceiling prices on drugs to narrow the difference between prices of branded and domestic generics. For imported patented drugs, international reference pricing is under consideration.
You may also be interested in...
China Rings In New Year With Major Deals, Record IPOs And Trends To Watch
From bringing innovative new drugs to global markets, to record-setting fundraisings and initial public offerings, five trends are emerging in China's health sector that are worth closely watching in 2021.
One Year On: WHO Probe In Wuhan, Mixed Vaccine Results For Sinovac
One year after the first cases of a novel coronavirus emerged in Wuhan, a team from the World Health Organization has arrived in the city to investigate its origin. Meanwhile, mixed results are reported for some of the leading Chinese vaccines being developed to fight the pandemic still wreaking global havoc.
Chi-Med's Surufatinib, Generic Ibrance Among Latest China Approvals
China's innovative drug makers step into the spotlight by grabbing green lights for cancer drugs in the country's latest batch of product approvals.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: